SEC Form 4 · accession 0002114900-26-000009
Krystal Biotech, Inc. · KRYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Charles Thomas
Officer — EVP, General Counsel
Period of report
Jun 25, 2026
Accepted (ET)
Jun 26, 2026 · 6:45 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001711279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 25, 2026 | M | 1,000 | $179.25 | A | 1,000 | D | |
| Common StockF1 | Jun 25, 2026 | S | 1,000 | $347.27 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $179.25 | Jun 25, 2026 | M | 1,000 | D | — | Feb 27, 2035 | Common Stock | 1,000 | 6,500 | D |
Explanation of responses
- F1The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms.
- F2The options vest ratably over a four-year period beginning on February 28, 2026.